Anti-C5 antibodies having improved pharmacokinetics
First Claim
Patent Images
1. An isolated antibody, or antigen-binding fragment thereof, that:
- (a) binds to complement component human C5;
(b) inhibits the cleavage of C5 into fragments C5a and C5b; and
(c) comprises;
(i) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
23, (ii) a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
19, (iii) a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
3, (iv) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
4, (v) a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
5, and (vi) a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
6, wherein the antibody has a serum half-life in humans of at least 40 days.
2 Assignments
0 Petitions
Accused Products
Abstract
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
66 Citations
10 Claims
-
1. An isolated antibody, or antigen-binding fragment thereof, that:
- (a) binds to complement component human C5;
(b) inhibits the cleavage of C5 into fragments C5a and C5b; and
(c) comprises;
(i) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
23, (ii) a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
19, (iii) a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
3, (iv) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
4, (v) a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
5, and (vi) a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
6, wherein the antibody has a serum half-life in humans of at least 40 days. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- (a) binds to complement component human C5;
Specification